Symbiosis Expands Global Reach with Key Appointment of Angelika Rublack as Senior Business Development Manager

Stirling, UK – 13th June 2025 – Symbiosis Pharmaceutical Services (Symbiosis), a global contract manufacturing organisation (CMO) specialising in sterile manufacture of injectable drug products, has appointed Angelika Rublack as Senior Business Development Manager to support its expanding global client base and drive growth across several territories.

With 25 years of international sales and key account experience, the last 16 of which have been in the pharmaceutical industry, Angelika brings an extensive knowledge of sterile manufacturing and commercial fill-finish services.

She joins Symbiosis from global CDMO Siegfried, holding a range of senior commercial roles including Senior Business Development Manager and Head of Sales Office.

Based in Germany, Angelika will play a pivotal role in expanding Symbiosis’ presence across the EU, US and APAC territories, identifying new project opportunities and fostering long-term partnerships within the biopharmaceutical market. Her appointment underscores Symbiosis’ commitment to client-centric growth worldwide.

“I was drawn to Symbiosis because of the company’s clear dedication to meeting customer needs with passion, agility and transparency,” said Angelika.

“Their culture of collaboration, strategic focus and customer-first mindset aligns perfectly with my experience and values. I’m excited to bring new partnerships to the business and becoming an integral part of Symbiosis’ continued success.”

In her role, Angelika will focus on identifying and securing new project opportunities and nurturing client relationships, leveraging her deep knowledge of complex stakeholder environments and her extensive experience in collaborative, cross-functional client engagement.

“Angelika brings invaluable expertise in sterile manufacturing and commercial fill/finish, and a proven track record of fostering trusted relationships across the biopharma sector,” said Colin MacKay, CEO of Symbiosis. “Her appointment enhances our business development capabilities across Europe as we continue to grow our international client base.”

Angelika joins the company at a time of accelerating demand for flexible, responsive CMO partnerships. Symbiosis’ ability to offer rapid access to GMP sterile manufacturing slots and a reputation for first-class client services, positions the company as a preferred partner for biopharmaceutical companies bringing life-saving therapies to market.

ENDS

About Symbiosis Pharmaceutical Services:

Symbiosis Pharmaceutical Services (Symbiosis) is a world-class Contract Manufacturing Organisation (CMO) located in Stirling, UK, and is a specialist sterile GMP manufacturer of biopharmaceuticals for use in clinical trials and commercial sales globally. Symbiosis is MHRA-licensed and FDA-inspected and offers a range of services including the aseptic fill/finish of medicines into vials, analytical testing, QP release of product, inspection, labelling, packaging and GMP temperature-controlled storage and shipment of medicines.

The Symbiosis facilities in Stirling, Scotland, were designed for biologic and small molecule pharmaceutical production to support biotechnology and pharmaceutical companies worldwide requiring sterile injectable pharmaceutical products manufactured in short timeframes for clinical trial use and commercial supply.

Regulatory compliance, technical capability and operational flexibility are core to the Symbiosis value proposition along with direct access to a highly experienced team of life science experts. By adding value directly to the new drug development projects and the commercial manufacturing supply chain requirements of its clients, Symbiosis has demonstrated consistent annual growth and built long-term relationships with its client base globally.

For more information on Symbiosis visit http://www.symbiosis-pharma.com or follow us on LinkedIn.

Media Contact:
Rachael Heath
ramarketing
rachael@ramarketingpr.com
www.ramarketingpr.com